Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: A pilot retrospective study

American Journal of Roentgenology

Volumn 199, Issue 2, 2012, Pages 349-359

  Chung, Woo Suk ^a   Lee, Kwang Hun ^b   Park, Mi Suk ^a   Lee, Yeo Jin ^a   Kwon, Joonho ^a   Baek, Song Ee ^a   Kim, Myeong Jin ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

CT; Doxorubicin; Drug eluting beads; Hepatocellular carcinoma; Transarterial chemoembolization

Indexed keywords

DOXORUBICIN; IODIXANOL; IOPROMIDE;

ADULT; AGED; ARTICLE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG ELUTING BEAD; FEMALE; FOLLOW UP; HUMAN; IMPLANT; LIVER CELL CARCINOMA; MALE; PILOT STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TUMOR GROWTH;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; HUMANS; IOHEXOL; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PILOT PROJECTS; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84864739969     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.7563     Document Type: Article

References (35)

1. Liu Q, Song Y, Zhou Y, Qiao L. A useful agent for chemoprevention of hepatocellular carcinoma? Cancer Biol Ther 2006; 5:1674-1676
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156 (Pubitemid 32911406)
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236 (Pubitemid 43112690)
4. Hong K, Georgiades CS, Geschwind JF. Technology insight: image-guided therapies for hepatocellular carcinoma-intra-arterial and ablative techniques. Nat Clin Pract Oncol 2006; 3:315-324 (Pubitemid 43871542)
5. Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: a collective review. Eur J Surg Oncol 2005; 31:331-347 (Pubitemid 40521297)
6. Rhim H, Lim HK, Kim YS, Choi D, Lee WJ. Radiofrequency ablation of hepatic tumors: lessons learned from 3000 procedures. J Gastroenterol Hepatol 2008; 23:1492-1500
7. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35:519-524 (Pubitemid 34183954)
8. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329-338
9. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10:S115-S120 (Pubitemid 38240111)
10. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33:41-52
11. Malagari K, Pomoni M, Spyridopoulos TN, et al. Safety profile of sequential transcatheter chemoembolization with DC Bead: results of 237 hepatocellular carcinoma (HCC) patients. Cardiovasc Intervent Radiol 2011; 34:774-785
12. Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33:532-540
13. Song MJ, Park CH, Kim JD, et al. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol 2011; 23:521-527
14. Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33:541-551
15. Kalva SP, Iqbal SI, Yeddula K, et al. Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. Gastrointest Cancer Res 2011; 4:2-8
16. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30:52-60
17. Riaz A, Memon K, Miller FH, et al. Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. J Hepatol 2011; 54:695-704
18. Crewson PE. Reader agreement studies. AJR 2005; 184:1391-1397 (Pubitemid 43821805)
19. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33:159-174 (Pubitemid 8054849)
20. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006; 12:2563-2567
21. Malagari K. Drug-eluting particles in the treatment of HCC: chemoembolization with doxorubicin-loaded DC Bead. Expert Rev Anticancer Ther 2008; 8:1643-1650
22. Sadick M, Haas S, Loehr M, et al. Application of DC beads in hepatocellular carcinoma: clinical and radiological results of a drug delivery device for transcatheter superselective arterial embolization. Onkologie 2010; 33:31-37
23. Mannelli L, Kim S, Hajdu CH, Babb JS, Clark TW, Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR 2009; 193:1044-1052
24. Herber S, Biesterfeld S, Franz U, et al. Correlation of multislice CT and histomorphology in HCC following TACE: predictors of outcome. Cardiovasc Intervent Radiol 2008; 31:768-777
25. Hunt SJ, Yu W, Weintraub J, Prince MR, Kothary N. Radiologic monitoring of hepatocellular carcinoma tumor viability after transhepatic arterial chemoembolization: estimating the accuracy of contrast-enhanced cross-sectional imaging with histopathologic correlation. J Vasc Interv Radiol 2009; 20:30-38
26. Kim S, Mannelli L, Hajdu CH, et al. Hepatocellular carcinoma: assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 2010; 31:348-355
27. Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011; 55:1309-1316
28. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer 2012; 118:147-156
29. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430 (Pubitemid 32844200)
30. Ippolito D, Bonaffini PA, Ratti L, et al. Hepatocellular carcinoma treated with transarterial chemoembolization: dynamic perfusion-CT in the assessment of residual tumor. World J Gastroenterol 2010; 16:5993-6000
31. Bonekamp S, Jolepalem P, Lazo M, Gulsun MA, Kiraly AP, Kamel IR. Hepatocellular carcinoma: response to TACE assessed with semiautomated volumetric and functional analysis of diffusionweighted and contrast-enhanced MR imaging data. Radiology 2011; 260:752-761
32. Ross CJ, Rennert J, Schacherer D, et al. Image fusion with volume navigation of contrast enhanced ultrasound (CEUS) with computed tomography (CT) or magnetic resonance imaging (MRI) for post-interventional follow-up after transcatheter arterial chemoembolization (TACE) of hepatocellular carcinomas (HCC): preliminary results. Clin Hemorheol Microcirc 2010; 46:101-115
33. Bian DJ, Xiao EH, Hu DX, et al. Magnetic resonance spectroscopy on hepatocellular carcinoma after transcatheter arterial chemoembolization. Chin J Cancer 2010; 29:198-201
34. Kim KW, Lee JM, Klotz E, et al. Safety margin assessment after radiofrequency ablation of the liver using registration of preprocedure and postprocedure CT images. AJR 2011; 196:1091; [web]W565-W572
35. Tajima T, Nishie A, Asayama Y, et al. Safety margins of hepatocellular carcinoma demonstrated by 3-dimensional fused images of computed tomographic hepatic arteriography/unenhanced computed tomography: prognostic significance in patients who underwent transcatheter arterial chemoembolization. J Comput Assist Tomogr 2010; 34:712-719